US5180589A
(en)
*
|
1988-03-31 |
1993-01-19 |
E. R. Squibb & Sons, Inc. |
Pravastatin pharmaceuatical compositions having good stability
|
GR1002098B
(en)
*
|
1989-06-08 |
1995-12-28 |
Squibb & Sons Inc |
Pharmaceutical composition having good stability
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
HU221849B1
(hu)
*
|
1991-12-12 |
2003-02-28 |
Novartis Ag. |
HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények
|
HU9203780D0
(en)
*
|
1991-12-12 |
1993-03-29 |
Sandoz Ag |
Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
|
CA2150372C
(en)
*
|
1993-01-19 |
2002-08-20 |
Nancy L. Mills |
Stable oral ci-981 formulation and process of preparing same
|
US5506248A
(en)
*
|
1993-08-02 |
1996-04-09 |
Bristol-Myers Squibb Company |
Pharmaceutical compositions having good dissolution properties
|
WO1996026726A1
(en)
|
1995-02-28 |
1996-09-06 |
Hoechst Marion Roussel, Inc. |
Pharmaceutical composition for piperidinoalkanol compounds
|
AU725622B2
(en)
*
|
1995-12-22 |
2000-10-19 |
Kowa Company, Ltd. |
Pharmaceutical composition stabilized with a basic agent
|
US5958453A
(en)
*
|
1996-10-31 |
1999-09-28 |
Takeda Chemical Industries, Ltd. |
Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
|
DE19724123A1
(de)
|
1997-06-09 |
1998-12-10 |
Voith Sulzer Papiermasch Gmbh |
Vorrichtung und Verfahren zum Überführen eines Einfädelstreifens oder einer Materialbahn
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
HUP0100433A3
(en)
*
|
1997-12-22 |
2003-01-28 |
Schering Corp |
Orally administrable solid ribavirin dosage forms and process for producing them
|
US5916594A
(en)
*
|
1997-12-22 |
1999-06-29 |
Schering Corporation |
Process of making solid ribavirin dosage forms
|
US5914128A
(en)
*
|
1997-12-22 |
1999-06-22 |
Schering Corporation |
Orally administrable solid dosage form
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
KR100281521B1
(ko)
*
|
1998-03-31 |
2001-02-15 |
김종인 |
프라바스타틴나트륨이 함유된 약제 조성물
|
DK2263660T3
(da)
|
1998-05-18 |
2018-01-02 |
Takeda Pharmaceuticals Co |
Oralt desintegrerende tabletter.
|
US6232351B1
(en)
*
|
1998-05-22 |
2001-05-15 |
Amway Corporation |
Co-processed botanical plant composition
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
EP1100469B1
(en)
|
1998-07-28 |
2005-03-23 |
Takeda Pharmaceutical Company Limited |
Rapidly disintegrable solid preparation
|
US5985907A
(en)
*
|
1998-08-12 |
1999-11-16 |
Health Research, Inc. |
Method for inhibiting growth of methanogens
|
SI20109A
(sl)
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
US6391583B1
(en)
|
1998-12-18 |
2002-05-21 |
Wisconsin Alumni Research Foundation |
Method of producing antihypercholesterolemic agents
|
US6838091B2
(en)
|
1998-12-18 |
2005-01-04 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US7014864B1
(en)
|
1998-12-18 |
2006-03-21 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6814977B1
(en)
|
1998-12-18 |
2004-11-09 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
US6719999B2
(en)
|
1999-03-31 |
2004-04-13 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
EP1165141A2
(en)
*
|
1999-03-31 |
2002-01-02 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
US6465011B2
(en)
|
1999-05-29 |
2002-10-15 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6372251B2
(en)
|
1999-06-11 |
2002-04-16 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
GB0001621D0
(en)
|
2000-01-26 |
2000-03-15 |
Astrazeneca Ab |
Pharmaceutical compositions
|
USRE44578E1
(en)
|
2000-04-10 |
2013-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
|
PT2382970E
(pt)
*
|
2000-04-10 |
2013-02-18 |
Teva Pharma |
Composições farmacêuticas estáveis que contêm ácidos 7- substituído-3,5-dihidroxiheptanóicos ou ácidos 7-substituído- 3,5-dihidroxiheptenóicos
|
US6242003B1
(en)
*
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
CZ20023826A3
(cs)
|
2000-06-09 |
2003-04-16 |
Lek Pharmaceuticals D. D. |
Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
|
CZ20024015A3
(cs)
|
2000-06-09 |
2003-04-16 |
Lek Pharmaceutical D.D. |
Stabilní farmaceutický produkt a jeho formulace
|
US6806290B2
(en)
|
2000-06-09 |
2004-10-19 |
Lek Pharmaceuticals D.D. |
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
|
US20020183383A1
(en)
*
|
2001-02-27 |
2002-12-05 |
Rene Belder |
Pharmaceutical compositions
|
BR0208504A
(pt)
*
|
2001-03-27 |
2004-03-09 |
Ranbaxy Lab Ltd |
Composição farmacêutica estável de pravastatina
|
US20060127474A1
(en)
*
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
GB0111077D0
(en)
*
|
2001-05-04 |
2001-06-27 |
Biochemie Gmbh |
Organic compounds
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
JP2004536826A
(ja)
*
|
2001-06-21 |
2004-12-09 |
アンドルックス ファーマスーティカルズ インコーポレーテッド |
プラバスタチンを含む安定な薬剤組成物
|
US7838026B2
(en)
|
2001-09-28 |
2010-11-23 |
Mcneil-Ppc, Inc. |
Burst-release polymer composition and dosage forms comprising the same
|
US7122143B2
(en)
|
2001-09-28 |
2006-10-17 |
Mcneil-Ppc, Inc. |
Methods for manufacturing dosage forms
|
US7323192B2
(en)
*
|
2001-09-28 |
2008-01-29 |
Mcneil-Ppc, Inc. |
Immediate release tablet
|
EP1905431A1
(en)
*
|
2002-01-11 |
2008-04-02 |
Circ Pharma Research and Development Limited |
Pravastatin pharmaceutical formulations and methods of their use
|
WO2003057195A1
(en)
*
|
2002-01-11 |
2003-07-17 |
Athpharma Limited |
Pravastatin pharmaceutical formulations and methods of their use
|
AU2002244881A1
(en)
*
|
2002-03-22 |
2003-10-08 |
Ranbaxy Laboratories Limited |
Controlled release drug delivery system of pravastatin
|
WO2003088900A2
(en)
*
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Solid forms of salts with tyrosine kinase activity
|
EP1551356A2
(en)
*
|
2002-09-03 |
2005-07-13 |
Biovail Laboratories Incorporated |
Pravastatin pharmaceutical formulations and methods of their use
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
CA2508840A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
PT1596870E
(pt)
|
2002-12-20 |
2007-10-15 |
Hoffmann La Roche |
Formulação com uma dose elevada de ibandronato
|
US7276536B2
(en)
*
|
2003-03-17 |
2007-10-02 |
Japan Tobacco Inc. |
Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
|
CA2519432C
(en)
*
|
2003-03-17 |
2009-06-09 |
Japan Tobacco Inc. |
Pharmaceutical compositions comprising cetp inhibitors and a water-insoluble concentration-enhancing additive for the treatment of cardiovascular disease
|
TWI494102B
(zh)
*
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
CN1839114A
(zh)
|
2003-08-21 |
2006-09-27 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
JP2007512359A
(ja)
|
2003-11-19 |
2007-05-17 |
メタバシス・セラピューティクス・インコーポレイテッド |
新規なリン含有甲状腺ホルモン様物質
|
US8163797B2
(en)
*
|
2003-12-31 |
2012-04-24 |
Actavis Elizabeth Llc |
Method of treating with stable pravastatin formulation
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
WO2006008757A2
(en)
*
|
2004-05-05 |
2006-01-26 |
Cadila Healthcare Limited |
Stabilized pharmaceutical compositions of pravastatin
|
CA2576196A1
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel statin pharmaceutical compositions and related methods of treatment
|
CA2573316A1
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
CN100453116C
(zh)
*
|
2004-10-19 |
2009-01-21 |
上海中西制药有限公司 |
复方氨茶碱片剂及其制备方法
|
CA2588216A1
(en)
*
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Stable atorvastatin formulations
|
NZ555316A
(en)
|
2004-12-09 |
2009-08-28 |
Merck & Co Inc |
Estrogen receptor modulators
|
ES2510494T3
(es)
|
2005-03-02 |
2014-10-21 |
Merck Sharp & Dohme Corp. |
Composición para la inhibición de la catepsina K
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
TW200804345A
(en)
*
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
ES2654847T3
(es)
|
2006-04-19 |
2018-02-15 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
|
WO2008027557A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Spherics, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
EP1911441A3
(en)
*
|
2006-10-11 |
2008-08-06 |
Lupin Limited |
Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
DE07870164T1
(de)
|
2006-11-17 |
2009-02-19 |
Supernus Pharmaceuticals, Inc. |
Verzögert freigesetzte formulierungen aus topiramat
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
JP5330274B2
(ja)
|
2007-03-01 |
2013-10-30 |
ノバルティス アーゲー |
Pimキナーゼ阻害剤およびその使用方法
|
US20080249141A1
(en)
*
|
2007-04-06 |
2008-10-09 |
Palepu Nageswara R |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
WO2008124122A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent and glitazones
|
WO2008124120A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent
|
ES2452349T3
(es)
|
2007-05-21 |
2014-04-01 |
Novartis Ag |
Inhibidores de CSF-1R, composiciones, y métodos de uso
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
JP5539221B2
(ja)
|
2007-12-21 |
2014-07-02 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
選択的アンドロゲン受容体モジュレーター(sarm)およびその使用
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
CN101732267B
(zh)
*
|
2008-11-14 |
2012-05-30 |
丽珠医药集团股份有限公司 |
普伐他汀钠片剂、其用途及其制备方法
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
CA2777043C
(en)
|
2009-10-14 |
2015-12-15 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
JP5829607B2
(ja)
*
|
2010-06-30 |
2015-12-09 |
持田製薬株式会社 |
ω3脂肪酸の配合製剤
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP4079856A1
(en)
|
2010-08-17 |
2022-10-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
US8697132B2
(en)
|
2010-12-01 |
2014-04-15 |
Shire Llc |
Capsule and powder formulations containing lanthanum compounds
|
US8263119B2
(en)
*
|
2010-12-01 |
2012-09-11 |
Shire Llc |
Capsule formulations containing lanthanum compounds
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US8791162B2
(en)
|
2011-02-14 |
2014-07-29 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2012141160A1
(ja)
|
2011-04-12 |
2012-10-18 |
沢井製薬株式会社 |
ピタバスタチン含有製剤及びその製造方法
|
EP2699567A1
(en)
|
2011-04-21 |
2014-02-26 |
Merck Sharp & Dohme Corp. |
Insulin-like growth factor-1 receptor inhibitors
|
WO2012153181A1
(en)
*
|
2011-05-11 |
2012-11-15 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
KR101466617B1
(ko)
*
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
TWI636783B
(zh)
*
|
2012-04-18 |
2018-10-01 |
友霖生技醫藥股份有限公司 |
含匹伐他汀(pitavastatin)穩定配方的醫藥組合物
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
SI2925888T1
(en)
|
2012-11-28 |
2018-02-28 |
Merck Sharp & Dohme Corp. |
Compounds and methods for the treatment of cancer
|
RU2690663C2
(ru)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Замещенные имидазопиридины в качестве ингибиторов hdm2
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
IN2013MU02470A
(da)
*
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN105593230B
(zh)
|
2013-10-08 |
2018-07-06 |
默沙东公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015108988A2
(en)
|
2014-01-17 |
2015-07-23 |
Ligand Pharmaceuticals, Inc. |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
US10413543B2
(en)
*
|
2015-09-01 |
2019-09-17 |
Sun Pharma Advanced Research Company Ltd. |
Stable multiparticulate pharmaceutical composition of rosuvastatin
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2021126731A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2024180169A1
(en)
|
2023-03-02 |
2024-09-06 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|